Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Should You Scoop Up Shares of This Promising Biotech on the Dip?
06:27am, Thursday, 28'th Oct 2021
This gene-editing specialist could still be an excellent long-term play.
Is It Time To Bet On Editas Stock's Next Leg Lower?
01:24pm, Wednesday, 27'th Oct 2021
It's been a volatile year for Editas Medicine (EDIT).
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
04:01pm, Monday, 25'th Oct 2021
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,
Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More
03:18pm, Tuesday, 19'th Oct 2021
Another day of strong earnings is pushing the broad markets higher across the board.
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful
02:25pm, Tuesday, 19'th Oct 2021
EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech. The post Editas Medicine Could Skyrocket if Its Gene Editi
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
12:38pm, Thursday, 14'th Oct 2021
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
11:30am, Wednesday, 13'th Oct 2021
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
What's Hot in the Stock Market?
03:15pm, Monday, 11'th Oct 2021
We've got a look at Merck and Amazon and Warby Parker and more.
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progre
Editas Medicine, Inc (EDIT) Management Presents at Chardan's 5th Annual Genetic Medicines Conference (Transcript)
01:47pm, Monday, 04'th Oct 2021
Editas Medicine, Inc (EDIT) Management Presents at Chardan's 5th Annual Genetic Medicines Conference (Transcript)
Is The Selling In Editas Stock Overdone?
09:00am, Friday, 01'st Oct 2021
The stock price of Editas plunged 19% in yesterday's trading session after the company shared interim data for its EDIT 101 - a CRISPR-based treatment for Leber congenital amaurosis. The data showed t
Editas (EDIT) Down on Initial Data From Eye Disease Study
11:54am, Thursday, 30'th Sep 2021
Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.
Editas Medicine to Present at Chardan's 5th Annual Genetic Medicines Conference
08:00am, Thursday, 30'th Sep 2021
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present at Chardan's 5th Annual Genetic Medicines Conference on Monday
4 Top Stock Trades for Thursday: LCID, DKNG, DLTR, EDIT
05:49pm, Wednesday, 29'th Sep 2021
Lucid Motors, DraftKings, Dollar Tree and Editas Medicine were our top stock trades for Thursday. Now, let's look at how the charts set up.
LSPD Stock: Why This Analyst Report Predicts Up to 80% Downside for Lightspeed Commerce
01:39pm, Wednesday, 29'th Sep 2021
Lightspeed Commerce (LSPD) stock is on the rise Wednesday following the release of a short report taking the company to task. The post LSPD Stock: Why This Analyst Report Predicts Up to 80% Downside f
